Preterm birth · pregnant women
Potent/very potent topical corticosteroids may leads to higher preterm delivery compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.05
47651 participants
Low
Foetal death · pregnant women
Potent/very potent topical corticosteroids may leads to higher foetal death compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.14
37086 participants
Low
Low Apgar score · pregnant women
Potent/very potent topical corticosteroids may leads to higher low Apgar score compared with no topical corticosteroids (low certainty).
1 finding from 1 review
RR 1.03
7514 participants
Low
Complete resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher complete resolution of phimosis compared with placebo or no treatment (low certainty).
2 findings from 1 review
Partial resolution of phimosis · boys up to 18 years old with phimosis
Topical corticosteroids may leads to higher partial resolution of phimosis compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in retractability score · boys up to 18 years old with phimosis
It is very uncertain whether topical corticosteroids changes change in retractability score compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse effects (any) · boys up to 18 years old with phimosis
Topical corticosteroids showed no clear difference in adverse effects (any) compared with placebo or no treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Risk of secondary hemorrhage; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids may leads to lower risk of secondary hemorrhage; oral corticosteroids compared with placebo or control treatment (low certainty).
1 finding from 1 review
Total amount of topical corticosteroids used · people with eczema
1 finding from 1 review
Total amount of topical corticosteroids used · people with eczema
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment probably leads to higher primary: investigator‐rated good/excellent control of symptoms compared with vehicle (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Primary: adverse events ‐ burning/itching at application site · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
Topical calcineurin inhibitors: tacrolimus 0.1% ointment showed no clear difference in primary: adverse events ‐ burning/itching at application site compared with vehicle (moderate certainty).
1 finding from 1 review
Secondary: investigator‐rated reduction in severity ‐ Not measured · people with moderate to severe nickel sulphate‐induced allergic contact dermatitis based on clinical history (hand eczema) and proven by…
The review found no eligible studies for this question.
1 finding from 1 review
Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis
Tacrolimus 0.03% probably leads to higher physician's assessment of global response of improvement, clear or… compared with corticosteroids (moderate certainty).
4 findings from 1 review
RR 2.05 [1.36, 3.08]
1 study · 411 participants
Moderate
RR 2.58 [1.96, 3.38]
2 studies · 790 participants
Moderate
RR 0.45 [0.13, 1.57]
2 studies · 409 participants
Very low
Show 1 more finding
Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).
1 finding from 1 review
Patient‐reported symptoms of eczema · children and adults, most with moderate to severe eczema
Potent may leads to lower patient‐reported symptoms of eczema: PGA; short‐term (week 1) compared with moderate‐potency topical corticosteroid (low certainty).
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review